No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CLDX250117C34000
- 0.00
- 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest34.00Strike Price0.00Turnover0.00%IV39.63%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $90
Citi Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $70
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Calculating The Intrinsic Value Of Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Is There An Opportunity With Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) 26% Undervaluation?
Express News | Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis